# CAVATAK (CVA21) in Non-muscle Invasive Bladder Cancer (VLA-012 CANON)

> **NCT02316171** · PHASE1 · COMPLETED · sponsor: **Viralytics** · enrollment: 16 (actual)

## Conditions studied

- Non-muscle Invasive Bladder Cancer

## Interventions

- **BIOLOGICAL:** CVA21
- **DRUG:** Mitomycin C

## Key facts

- **NCT ID:** NCT02316171
- **Lead sponsor:** Viralytics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-16
- **Primary completion:** 2016-03-14
- **Final completion:** 2016-03-14
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2022-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02316171

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02316171, "CAVATAK (CVA21) in Non-muscle Invasive Bladder Cancer (VLA-012 CANON)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02316171. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*